LABU News and Press, Direxion Daily S&P Biotech Bull 3X Shares From 01/08/24

2024-01-08 08:31:52 ET Summary The healthcare sector was flat in 2023 year as a result of some unique issues. Drug price regulation will be a serious challenge for the sector this year. Defensive healthcare industry groups should do well during the first half and biotechnology...

2024-01-07 04:45:00 ET Summary Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Suzhou MediLink Therapeutics out-licensed global rights for its pre-clinical c-Mesenchymal epithelial transition factor ADC to R...

2024-01-06 08:15:00 ET Summary Global equity markets experienced a surge in 2023 driven by economic growth and investor confidence. US equity returns exceeded expectations despite concerns about higher rates, inflation, and geopolitical tension. In 2024, investors should focus...

2024-01-05 17:56:37 ET Summary Shorting and inverse bets don't work over time on average, making inverse funds like Direxion Daily S&P Biotech Bear 3X Shares ETF a big avoid. The LABD ETF is a triple-leveraged inverse ETF that focuses on the biotechnology sector and aims to pr...

2024-01-02 17:00:00 ET Summary Leveraged ETFs often underperform their underlying index due to beta-slippage. Monthly and yearly drift can be monitored to assess the performance of leveraged ETFs relative to their underlying index. ProShares UltraPro Dow30 (UDOW) has experienc...

2023-12-27 11:16:29 ET Direxion Daily S&P Biotech Bull 3X Shares ( NYSEARCA: LABU ) declares $0.2097/share semi-annual dividend. Payable Dec. 29; for shareholders of record Dec. 22; ex-div Dec. 21. See LABU Dividend Scorecard, Yield Chart, & Dividend Growth. ...

2023-12-21 08:25:00 ET Summary Given strong recent market returns and another wave of capital inflows, the backdrop is probably not enough to lead to strong tactical performance from risk assets. The US has a more favorable demographic trend; its working-age population is expected...

2023-12-20 06:19:00 ET Summary Can the Magnificent 7 continue to rally into 2024? How the Magnificent 7's rise compares to the dot-com bubble. Why the rise in tech stocks highlights shortcomings for the markets. The rise of the Magnificent 7 tech stocks has been a ke...

2023-12-16 13:48:00 ET More on weekly ETF movers LABU: Tool For Swing Traders PALL: The Palladium Premium Over Platinum Collapses PALL: Blessing Turn Into A Curse LABU, TZA and LABD among weekly ETF movers Investors inject capital into the fund market...

2023-12-16 08:35:19 ET Summary Seeking Alpha Quant rates LABU as a strong Sell, but I rates it as a Buy due to bullish market conditions. LABU is a leveraged ETF that seeks to track 3x the daily performance of the S&P Biotechnology Select Industry Index. I believe LABU has...